Torsdag 26 Juni | 15:24:04 Europe / Stockholm

Kalender

Est. tid*
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-04-07 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2025-04-04 - Årsstämma
2025-03-07 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-05 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2024-04-04 - Årsstämma
2024-03-07 - Bokslutskommuniké 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-03-31 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2023-03-30 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-06 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2022-04-05 - Årsstämma
2022-03-02 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorInformationsteknik
IndustriProgramvara
Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden från onkologi till neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.
2025-06-24 17:30:00

The Board of Directors of Aiforia Technologies Plc decided on new Stock Option Plan

Aiforia Technologies Plc, Stock Exchange Release, June 24, 2025 at 6:30 p.m. EEST

The Board of Directors of Aiforia Technologies Plc has decided to launch a new stock option plan 2025A-C for a key consultant of the company based on the authorization given by the Annual General Meeting of Shareholders on April 4, 2025. The company has a weighty financial reason for the issue of stock options, since the stock options are intended to promote long-term commitment and cooperation between the company and the consultant to increase shareholder value.

The maximum total number of stock options 2025A-C issued is 298,200 and they entitle their owners to subscribe for a maximum total of 298,200 new shares in the company or existing shares held by the company. Of the stock options 99,400 are marked with the symbol 2025A, 99,400 are marked with the symbol 2025B, and 99,400 are marked with the symbol 2025C.

The shares subscribed for with the stock options to be issued will account for a total maximum of 0.95 per cent of all the company's shares and votes after possible share subscriptions if new shares are issued in the subscription. As a result of the share subscriptions made with the stock options, the number of shares in the company may increase by a total maximum of 298,200 shares if new shares are issued in the subscription.

The share subscription period for stock options 2025A will be 1 June 2026–31 December 2028.
The share subscription period for stock options 2025B will be 1 June 2027–31 December 2028.
The share subscription period for stock options 2025C will be 1 June 2028–31 December 2028.

The share subscription price for the stock options 2025A-C is EUR 3.64 per share, which corresponds to the trade volume weighted average quotation of the Company’s share on the First North Growth Market Finland from 1 January 2025 to 31 March 2025. The share subscription price will be credited to the company's reserve for invested unrestricted equity.

The theoretical market value of one stock option 2025A-C is approximately EUR 1.017. The theoretical market value of the stock options 2025A-C is approximately EUR 303,270 in total. The theoretical market value of a stock option has been calculated by using the Black & Scholes model taking into account the subscription price of the stock option and the following input factors: share price EUR 3.22, risk-free interest rate 2.08%, validity of stock options 3.5 years, volatility approximately 45.65% and expected dividend yield 0%.

Further inquiries 
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 405 009 878
https://investors.aiforia.com/

Certified Adviser 
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

 

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com